Ovid Therapeutics Inc. (OVID) stock
OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 10/30
$2.26+0.04 (+1.80%)
Close on Nov 18, 2026Market cap $441.37MP/E –Yield –
Ovid Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Ovid Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$58.36M. For fiscal 2025 it was -$42.44M. The highest annual figure on record is $124.21M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$42.44M | – |
| FY2024 | Dec 31, 2024 | -$61.89M | – |
| FY2023 | Dec 31, 2023 | -$59.28M | – |
| FY2022 | Dec 31, 2022 | -$55.55M | -144.7% |
| FY2021 | Dec 31, 2021 | $124.21M | – |
| FY2020 | Dec 31, 2020 | -$81.43M | – |
| FY2019 | Dec 31, 2019 | -$61.41M | – |
| FY2018 | Dec 31, 2018 | -$52.93M | – |
| FY2017 | Dec 31, 2017 | -$65.01M | – |
| FY2016 | Dec 31, 2016 | -$22.54M | – |
| FY2015 | Dec 31, 2015 | -$13.19M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$15.70M | – |
| Q1 FY2026 | Mar 31, 2026 | -$17.85M | – |
| Q4 FY2025 | Dec 31, 2025 | -$12.29M | – |
| Q3 FY2025 | Sep 30, 2025 | -$12.52M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.07M | – |
| Q1 FY2025 | Mar 31, 2025 | -$12.55M | – |
| Q4 FY2024 | Dec 31, 2024 | -$10.72M | – |
| Q3 FY2024 | Sep 30, 2024 | -$13.23M | – |
| Q2 FY2024 | Jun 30, 2024 | -$20.52M | – |
| Q1 FY2024 | Mar 31, 2024 | -$17.42M | – |
| Q4 FY2023 | Dec 31, 2023 | -$18.19M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.03M | – |
| Q2 FY2023 | Jun 30, 2023 | -$14.17M | – |
| Q1 FY2023 | Mar 31, 2023 | -$14.89M | – |
| Q4 FY2022 | Dec 31, 2022 | -$12.17M | – |
| Q3 FY2022 | Sep 30, 2022 | -$12.80M | – |
| Q2 FY2022 | Jun 30, 2022 | -$14.30M | – |
| Q1 FY2022 | Mar 31, 2022 | -$16.27M | -109.2% |
| Q4 FY2021 | Dec 31, 2021 | -$26.35M | – |
| Q3 FY2021 | Sep 30, 2021 | -$11.68M | – |
| Q2 FY2021 | Jun 30, 2021 | -$14.31M | – |
| Q1 FY2021 | Mar 31, 2021 | $176.56M | – |
| Q4 FY2020 | Dec 31, 2020 | -$21.59M | – |
| Q3 FY2020 | Sep 30, 2020 | -$16.40M | – |
| Q2 FY2020 | Jun 30, 2020 | -$23.14M | – |
| Q1 FY2020 | Mar 31, 2020 | -$20.29M | – |
| Q4 FY2019 | Dec 31, 2019 | -$17.27M | – |
| Q3 FY2019 | Sep 30, 2019 | -$16.77M | – |
| Q2 FY2019 | Jun 30, 2019 | -$13.32M | – |
| Q1 FY2019 | Mar 31, 2019 | -$14.05M | – |
| Q4 FY2018 | Dec 31, 2018 | -$13.13M | – |
| Q3 FY2018 | Sep 30, 2018 | -$13.18M | – |
| Q2 FY2018 | Jun 30, 2018 | -$13.21M | – |
| Q1 FY2018 | Mar 31, 2018 | -$13.43M | – |
| Q4 FY2017 | Dec 31, 2017 | -$11.05M | – |
| Q3 FY2017 | Sep 30, 2017 | -$9.41M | – |
| Q2 FY2017 | Jun 30, 2017 | -$10.29M | – |
| Q1 FY2017 | Mar 31, 2017 | -$34.26M | – |
| Q4 FY2016 | Dec 31, 2016 | -$7.59M | – |
| Q3 FY2016 | Sep 30, 2016 | -$5.81M | – |
See a number that looks wrong?